Dipesh H. Vasant

Dr. Dipesh H. Vasant


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 April 2021 in Gut
Verified
Journal Article
Open access
PDF file
DVDipesh H. Vasant
Dipesh H. Vasant
PPPeter A Paine
Peter A Paine
CBChristopher J Black
Christopher J Black
LHLesley A Houghton
Lesley A Houghton
HEHazel A Everitt
Hazel A Everitt
AFAlexander C Ford
Alexander C Ford
Irritable bowel syndrome (IBS) remains one of the most common gastrointestinal disorders seen by clinicians in both primary and secondary care. Since publication of the last British Society of Gastroenterology (BSG) guideline in 2007, substantial advances have been made in understanding its complex pathophysiology, resulting in its re-classification as a disorder of gut-brain interaction, rather than a functional gastrointestinal disorder. Moreover, there has been a considerable amount of new evidence published concerning the diagnosis, investigation and management of IBS. The primary aim of this guideline, commissioned by the BSG, is to review and summarise the current evidence to inform and guide clinical practice, by providing a practical framework for evidence-based management of patients. One of the strengths of this guideline is that the recommendations for treatment are based on evidence derived from a comprehensive search of the medical literature, which was used to inform an update of a series of trial-based and network meta-analyses assessing the efficacy of dietary, pharmacological and psychological therapies in treating IBS. Specific recommendations have been made according to the Grading of Recommendations Assessment, Development and Evaluation system, summarising both the strength of the recommendations and the overall quality of evidence. Finally, this guideline identifies novel treatments that are in development, as well as highlighting areas of unmet need for future research.

1 June 2020 in The Lancet Gastroenterology & Hepatology
Verified
Journal Article
Closed access
MHMark Hearn
Mark Hearn
PWPeter James Whorwell
Peter James Whorwell
DVDipesh H. Vasant
Dipesh H. Vasant

27 February 2019 in Neurogastroenterology & Motility
Verified
Journal Article
Open access
PDF file
DVDipesh H. Vasant
Dipesh H. Vasant
PWPeter James Whorwell
Peter James Whorwell
Background: Despite their high prevalence and advances in the field of neurogastroenterology, there remain few effective treatment options for functional gastrointestinal disorders (FGIDs). It is recognized that approximately 25% of sufferers will have symptoms refractory to existing therapies, causing significant adverse effects on quality of life and increased healthcare utilization and morbidity. Gut‐focused hypnotherapy, when delivered by trained therapists, has been shown to be highly effective in severe refractory FGIDs. However, hypnotherapy continues to be surrounded by much misunderstanding and skepticism.Purpose: The purpose of this review is to provide a contemporary overview of the principles of gut‐focused hypnotherapy, its effects on gut‐brain interactions, and the evidence‐base for its efficacy in severe FGIDs. As supplementary material, we have included a hypnotherapy protocol, providing the reader with an insight into the practical aspects of delivery, and as a guide, an example of a script of a gut‐focused hypnotherapy session.

14 July 2020 in World Journal of Gastroenterology
Verified
Journal Article
Open access
DVDipesh H. Vasant
Dipesh H. Vasant
AFAlexander C Ford
Alexander C Ford
Functional gastrointestinal disorders in inflammatory bowel disease: Time for a paradigm shift?

26 April 2019 in Neurogastroenterology & Motility
Verified
Journal Article
Closed access
PDF file
DVDipesh H. Vasant
Dipesh H. Vasant
ASAyodele Sasegbon
Ayodele Sasegbon
EMEmilia Michou
Emilia Michou
CSCraig Smith
Craig Smith
SHShaheen Hamdy
Shaheen Hamdy

9 April 2021 in Neurogastroenterology & Motility
Verified
Journal Article
Open access
PDF file
ASAyodele Sasegbon
Ayodele Sasegbon
DVDipesh H. Vasant
Dipesh H. Vasant
Irritable bowel syndrome (IBS) is a highly prevalent disorder of gut‐brain interaction, which significantly erodes the quality of life of those it affects. Recent studies have confirmed that its prevalence varies quite markedly between countries, implying that it is affected by cultural and socioeconomic factors. In an important study, Silvernale at al. have recently reported racial disparities including potential referral biases, with reduced opportunities to access specialist care and differing patterns of healthcare utilization affecting ethnic minority populations with IBS. Similar disparities have also been reported for other gastrointestinal disorders. In this paper, we, therefore, discuss the potential implications of such disparities and how they can impact clinical outcomes, and discuss ways in which this problem could be addressed, and highlighting areas for future research.